TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03455608

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RE-ACTIVE
Description: Reactive intervention started promptly if/when dysphagia is identified

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO-ACTIVE EAT
Description: Early low intensity proactive intervention started before RT commences

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PRO-ACTIVE EAT + EXERCISE
Description: Early high intensity proactive intervention started before RT commences
Study: NCT03271034

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weight loss
Description: Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian and/or behaviorist weekly for \~4 months.
Study: NCT03226444

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.005% Lacripep
Description: One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.01% Lacripep
Description: One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
Study: NCT01472055

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 1. Fludarabine 40 mg/m\^2 once a day intravenous administration over 30 min~2. Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr~3. Population pharmacokinetics analysis~4. Comparative analysis of population pharmacokinetics in pediatric and adult patients~5. Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate
Study: NCT03313739

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An Educational Program
Description: An educational program was designed for self-care during menopause using teach back method.
Study: NCT03129932

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: gluten phase
Description: 2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo phase
Description: 2 cakes without gluten will be consume during the 4 weeks of intervention
Study: NCT00565851

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT01795443

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.
Study: NCT02214056

Intervention type: OTHER
Intervention: Patient recruitment
Description: Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.

Intervention type: PROCEDURE
Intervention: Mobile team exam
Description: Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:~questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).~At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations.
Study: NCT02525718

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone
Description: If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.~(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively.
Study: NCT02558127

Intervention type: GENETIC
Intervention: Asthma patients
Description: Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.

Intervention type: GENETIC
Intervention: Asthma patients
Description: Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
Study: NCT03284229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Excimer Laser Coronary Atherectomy
Description: Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
Study: NCT04164121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide Tablets
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide Tablets
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenlarmide Tablets
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
Study: NCT01795443

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Measures - no vibration
Description: The movements required are performed without vibration.~The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.~The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself.
Study: NCT04164121

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Oral administration was conducted on an empty stomach, and the drug was administered once a day on day 1 and once a day from day 8 to day 17.
Study: NCT03311477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABBV-399
Description: Intravenous infusion
Study: NCT03505177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chitin-glucan fiber
Description: 4.5g per day of chitin-glucan during 3 weeks
Study: NCT01886859

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT01901419

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion
Description: Nitroglycerin infusion during rewarming

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitroglycerin infusion
Description: Nitroglycerin infusion during rewarming
Study: NCT04602078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg/m2
Description: Fixed dose of 1200 mg/m2 by intravenous (IV) infusion on D1 of each cycle up to disease progression, unacceptable toxicity or absence of clinical benefit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine 1000 mg/m2
Description: Gemcitabine 1000 mg/m2 IV on D1 and 1000 mg/m2 IV on D8 of each 21-day cycle for up to 6 cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 70 mg/m2
Description: Cisplatin 70 mg/m2 by IV on split-dose schedule of 35 mg/m2 on day 1 (D1) and 35 mg/m2 on day 8 (D8) for up to 6 cycles.
Study: NCT03392259

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone app
Description: Installment and use of smartphone app
Study: NCT02644395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorthalidone
Description: Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: Drug
Study: NCT01587859

Intervention type: PROCEDURE
Intervention: laparoscopic surgery
Description: Nissen fundoplication; Collis Gastroplasty.
Study: NCT02844218

Intervention type: OTHER
Intervention: Age of patient
Description: * Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)

Intervention type: OTHER
Intervention: Age of patient
Description: * Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)

Intervention type: OTHER
Intervention: Age of patient
Description: * Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.~* Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.~* Improvement of Treatments Over Time~* Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)
Study: NCT00550589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cidofovir
Description: 1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA methylation analysis
Description: formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
Study: NCT02378662

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MDGN201 TARGTEPO
Description: MDGN201 TARGTEPO secreting EPO
Study: NCT01701245

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GammaCore
Description: vagal stimulation
Study: NCT04486664

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Diet instruction and menu samples from the dietitian on following the Mediterranean Diet.
Study: NCT01081197

Intervention type: OTHER
Intervention: Psychiatric and somatic examinations and ,if clinical indicated, treatment
Description: Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
Study: NCT03424148

Intervention type: DEVICE
Group type: OTHER
Intervention: Excel V™ Laser & Micro-Lens Array Attach
Description: Subjects will receive laser treatments
Study: NCT03927092

Intervention type: OTHER
Intervention: Multiple Sclerosis Knowledge Questionnaire
Description: A 25-item self-administered questionnaire
Study: NCT03017859

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High flow nasal cannula
Description: We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
Study: NCT03984357

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 blocking antibody
Description: 1. Whole-course concurrent PD-1 blocking antibody: every 3 weeks × 6 cycles; 360 mg, day 1; start on day 1 of the first cycle IC and continue every 3 weeks for 6 cycles till the end of IMRT, involving the whole-course of IC + IMRT alone.~2. Adjuvant PD-1 blocking antibody: every 4 weeks × 6 cycles; 480 mg, day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine as induction chemotherapy, 1000 mg/m2 day 1, 8 per cycle, every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin as induction chemotherapy, 80 mg/m2 day 1 per cycle, every 3 weeks for 3 cycles

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiotherapy
Description: Definitive IMRT of 70 Gy, 33 fractions, 5 fractions/week, 1 fraction/day